Calling all Clinical Phase I Outsourcing Professionals!

Posted:
4
February 2007

Do You Outsource Phase I Clinical Trials?Outsourcing remains a critical aspect of clinical development. All major drug development projects rely on one or more partners to aid the drug development process. The 9th Annual Phase I Clinical Trials conference on 19-20 February at Olympia Conference Centre, London will highlight the following:

  • A timely update on the guidance for first man studies � the revision of EMEA guidelines
  • What are the challenges and priorities over the next five years for the MHRA
  • How to manage potentially 'high risk' complex molecules. Tegenero: a case study
  • The challenges of conducting phase I studies in patients

Get the answers you need to all your outsourcing questions and meet the team from Richmond Pharmacology, the Early Phase CRO that can help you achieve your goals.Wednesday 20 February 2008 at 2pm, Dr. Jörg Täubel MFPM, MD, Managing Director, Richmond Pharmacology, invites you to discuss "Why carry out Phase 1 Trials in the UK, focussing primarily on the regulatory implications of conducting Phase 1 studies in the UK".We look forward to meeting you at the Congress. Visit the Richmond Pharmacology team at Stand No 3 to discuss your Early Phase outsourcing requirements.Exhibitor DiscountAs exhibitors we are delighted to offer you a discount of 25% off the first person and 15% off each additional person after that if you would like to attend the conference. Please call Angela Davie, Business Development Manager, on 020 8664 5200 or book direct quoting our VIP CODE - TT30 and booking code TT30Spex.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more